Accelr8 Shares up 60 Percent on MRSA Dx Patent Allowance | GenomeWeb

Accelr8 Shares up 60 Percent on MRSA Dx Patent Allowance

Oct 18, 2007

NEW YORK (GenomeWeb News) — Shares in Accelr8 were up more than 60 percent this afternoon after the company said the US Patent and Trademark Office gave it a notice of allowance on the first patent related to its diagnostic platform.

Shares in the company were up 1.36 at $3.82 in late-afternoon trading today.

The company said the methods covered by the patent will enable its BACcel system to "quickly identify major multiple-drug-resistant bacteria and their resistance mechanisms."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Mouse Fight

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Seeing the Interactions

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

This Week in Science

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

For Millions

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.